The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-10-13

AUTHORS

Andrea Bever, Jackie Manthorne, Tissa Rahim, Layla Moumin, Shelagh M. Szabo

ABSTRACT

BackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib–IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data. More... »

PAGES

1-10

References to SciGraph publications

  • 2012-09-12. Sample Size Policy for Qualitative Studies Using In-Depth Interviews in ARCHIVES OF SEXUAL BEHAVIOR
  • 2019-12-17. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer in SIGNAL TRANSDUCTION AND TARGETED THERAPY
  • 2014-08-19. Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer in THE EUROPEAN JOURNAL OF HEALTH ECONOMICS
  • 1989-01. Measuring patients’ desire for autonomy in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2021-06-11. Conducting Qualitative Research Online: Challenges and Solutions in THE PATIENT - PATIENT-CENTERED OUTCOMES RESEARCH
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w

    DOI

    http://dx.doi.org/10.1007/s40271-021-00552-w

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141848861

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34643935


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Broadstreet HEOR, Vancouver, BC, Canada", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Broadstreet HEOR, Vancouver, BC, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bever", 
            "givenName": "Andrea", 
            "id": "sg:person.016336044014.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016336044014.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Canadian Cancer Survivor Network, Ottawa, ON, Canada", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Canadian Cancer Survivor Network, Ottawa, ON, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manthorne", 
            "givenName": "Jackie", 
            "id": "sg:person.07632772614.46", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07632772614.46"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Broadstreet HEOR, Vancouver, BC, Canada", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Broadstreet HEOR, Vancouver, BC, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rahim", 
            "givenName": "Tissa", 
            "id": "sg:person.012246573573.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246573573.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Canadian Cancer Survivor Network, Ottawa, ON, Canada", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Canadian Cancer Survivor Network, Ottawa, ON, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Moumin", 
            "givenName": "Layla", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Broadstreet HEOR, Vancouver, BC, Canada", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Broadstreet HEOR, Vancouver, BC, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Szabo", 
            "givenName": "Shelagh M.", 
            "id": "sg:person.0750556372.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750556372.03"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s41392-019-0099-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123443998", 
              "https://doi.org/10.1038/s41392-019-0099-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10508-012-0016-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035291402", 
              "https://doi.org/10.1007/s10508-012-0016-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02596485", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050744497", 
              "https://doi.org/10.1007/bf02596485"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40271-021-00528-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138780781", 
              "https://doi.org/10.1007/s40271-021-00528-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10198-014-0622-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050041525", 
              "https://doi.org/10.1007/s10198-014-0622-4"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-10-13", 
        "datePublishedReg": "2021-10-13", 
        "description": "BackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib\u2013IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s40271-021-00552-w", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1038760", 
            "issn": [
              "1178-1653", 
              "1178-1661"
            ], 
            "name": "The Patient - Patient-Centered Outcomes Research", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }
        ], 
        "keywords": [
          "disease-free survival", 
          "lung cancer", 
          "overall survival", 
          "trial endpoints", 
          "treatment goals", 
          "Canadian survivors", 
          "new treatments", 
          "meaningful treatment outcomes", 
          "curative-intent treatment", 
          "perspectives of survivors", 
          "lung cancer trials", 
          "clinical trial endpoints", 
          "intent treatment", 
          "patients' perceptions", 
          "cancer trials", 
          "patient outcomes", 
          "treatment outcomes", 
          "treatment decisions", 
          "treatment priorities", 
          "meaningful endpoints", 
          "cancer", 
          "ConclusionsThese findings", 
          "DFS data", 
          "survivors", 
          "cancer diagnosis", 
          "endpoint", 
          "survival", 
          "Most participants", 
          "patient agency", 
          "regulatory approval", 
          "treatment", 
          "potential surrogate", 
          "participants", 
          "outcomes", 
          "qualitative study", 
          "thematic analysis", 
          "qualitative interviews", 
          "chemotherapy", 
          "surgery", 
          "ResultsAmong", 
          "diagnosis", 
          "ObjectiveWe", 
          "trials", 
          "reimbursement", 
          "MethodsWeb", 
          "good indicator", 
          "approval", 
          "findings", 
          "individuals", 
          "response", 
          "surrogate", 
          "study", 
          "life", 
          "perception", 
          "interviews", 
          "priority", 
          "relevance", 
          "importance", 
          "experience", 
          "use", 
          "indicators", 
          "goal", 
          "patterns", 
          "access", 
          "data", 
          "quality", 
          "decisions", 
          "high quality", 
          "reasons", 
          "analysis", 
          "perspective", 
          "context", 
          "agencies"
        ], 
        "name": "The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer", 
        "pagination": "1-10", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141848861"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40271-021-00552-w"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34643935"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40271-021-00552-w", 
          "https://app.dimensions.ai/details/publication/pub.1141848861"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-10T10:29", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_895.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s40271-021-00552-w"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40271-021-00552-w'


     

    This table displays all metadata directly associated to this object as RDF triples.

    178 TRIPLES      22 PREDICATES      102 URIs      89 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40271-021-00552-w schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author Ne14c87317d8246bcacf122c5bb401233
    4 schema:citation sg:pub.10.1007/bf02596485
    5 sg:pub.10.1007/s10198-014-0622-4
    6 sg:pub.10.1007/s10508-012-0016-6
    7 sg:pub.10.1007/s40271-021-00528-w
    8 sg:pub.10.1038/s41392-019-0099-9
    9 schema:datePublished 2021-10-13
    10 schema:datePublishedReg 2021-10-13
    11 schema:description BackgroundIn lung cancer trials, overall survival is a well-validated and widely used endpoint; yet, in the context of adjuvant or curative intent treatments, disease-free survival (DFS) may be a better indicator of transformative patient outcomes. Although use of DFS is growing, patient perceptions of its relevance have not been established.ObjectiveWe aimed to understand the importance of DFS as a trial endpoint, from the perspective of survivors of lung cancer.MethodsWeb-based qualitative interviews were conducted with Canadian survivors of stage Ib–IIIa lung cancer. Participants described their experiences of cancer diagnosis and treatment, including their treatment goals and priorities. Participants then provided their perspectives on DFS and overall survival, and how well each aligned with their treatment priorities. Thematic analysis was used to explore patterns in responses.ResultsAmong the 18 participants (mean age, 64 years), 83% were female, most (89%) had received surgery, and 56% received chemotherapy. Most participants viewed DFS as an intrinsically meaningful treatment outcome, for reasons such as alignment with treatment goals, and the perception that DFS would help maintain a high quality of life. One individual was interested in DFS only as a potential surrogate for overall survival. Participants desired access to new treatments that improve DFS and emphasized this within the context of promoting patient agency in treatment decision making.ConclusionsThese findings suggest DFS is a meaningful endpoint from the perspective of survivors of lung cancer; and may help inform decisions regarding regulatory approval and reimbursement of new treatments based on DFS data.
    12 schema:genre article
    13 schema:inLanguage en
    14 schema:isAccessibleForFree false
    15 schema:isPartOf sg:journal.1038760
    16 schema:keywords Canadian survivors
    17 ConclusionsThese findings
    18 DFS data
    19 MethodsWeb
    20 Most participants
    21 ObjectiveWe
    22 ResultsAmong
    23 access
    24 agencies
    25 analysis
    26 approval
    27 cancer
    28 cancer diagnosis
    29 cancer trials
    30 chemotherapy
    31 clinical trial endpoints
    32 context
    33 curative-intent treatment
    34 data
    35 decisions
    36 diagnosis
    37 disease-free survival
    38 endpoint
    39 experience
    40 findings
    41 goal
    42 good indicator
    43 high quality
    44 importance
    45 indicators
    46 individuals
    47 intent treatment
    48 interviews
    49 life
    50 lung cancer
    51 lung cancer trials
    52 meaningful endpoints
    53 meaningful treatment outcomes
    54 new treatments
    55 outcomes
    56 overall survival
    57 participants
    58 patient agency
    59 patient outcomes
    60 patients' perceptions
    61 patterns
    62 perception
    63 perspective
    64 perspectives of survivors
    65 potential surrogate
    66 priority
    67 qualitative interviews
    68 qualitative study
    69 quality
    70 reasons
    71 regulatory approval
    72 reimbursement
    73 relevance
    74 response
    75 study
    76 surgery
    77 surrogate
    78 survival
    79 survivors
    80 thematic analysis
    81 treatment
    82 treatment decisions
    83 treatment goals
    84 treatment outcomes
    85 treatment priorities
    86 trial endpoints
    87 trials
    88 use
    89 schema:name The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer
    90 schema:pagination 1-10
    91 schema:productId N9afedbb4f2cc4f1f8f919581e936a040
    92 Na586d4d08a1e4a9faa03ebff82ffdb6d
    93 Nc16f0c7eae7b46d4b7f63dc360cfd420
    94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141848861
    95 https://doi.org/10.1007/s40271-021-00552-w
    96 schema:sdDatePublished 2022-05-10T10:29
    97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    98 schema:sdPublisher Nc65ebbcf37ad4cbdaaa7a1de70db8fdd
    99 schema:url https://doi.org/10.1007/s40271-021-00552-w
    100 sgo:license sg:explorer/license/
    101 sgo:sdDataset articles
    102 rdf:type schema:ScholarlyArticle
    103 N0ef9dcc4cc5d42db9f1c188a622597e1 rdf:first sg:person.07632772614.46
    104 rdf:rest Nb88af9402c194d1aa017e5064fd8e189
    105 N9afedbb4f2cc4f1f8f919581e936a040 schema:name doi
    106 schema:value 10.1007/s40271-021-00552-w
    107 rdf:type schema:PropertyValue
    108 Na3510ac3846d4c4eabf57dbe091dca52 schema:affiliation grid-institutes:None
    109 schema:familyName Moumin
    110 schema:givenName Layla
    111 rdf:type schema:Person
    112 Na586d4d08a1e4a9faa03ebff82ffdb6d schema:name pubmed_id
    113 schema:value 34643935
    114 rdf:type schema:PropertyValue
    115 Nb88af9402c194d1aa017e5064fd8e189 rdf:first sg:person.012246573573.48
    116 rdf:rest Nd580e37d78e541ff990051910cf8b2e8
    117 Nc16f0c7eae7b46d4b7f63dc360cfd420 schema:name dimensions_id
    118 schema:value pub.1141848861
    119 rdf:type schema:PropertyValue
    120 Nc65ebbcf37ad4cbdaaa7a1de70db8fdd schema:name Springer Nature - SN SciGraph project
    121 rdf:type schema:Organization
    122 Nd3b688fe3eb44815b07fb9cc3206cdbd rdf:first sg:person.0750556372.03
    123 rdf:rest rdf:nil
    124 Nd580e37d78e541ff990051910cf8b2e8 rdf:first Na3510ac3846d4c4eabf57dbe091dca52
    125 rdf:rest Nd3b688fe3eb44815b07fb9cc3206cdbd
    126 Ne14c87317d8246bcacf122c5bb401233 rdf:first sg:person.016336044014.46
    127 rdf:rest N0ef9dcc4cc5d42db9f1c188a622597e1
    128 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    129 schema:name Medical and Health Sciences
    130 rdf:type schema:DefinedTerm
    131 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    132 schema:name Oncology and Carcinogenesis
    133 rdf:type schema:DefinedTerm
    134 sg:journal.1038760 schema:issn 1178-1653
    135 1178-1661
    136 schema:name The Patient - Patient-Centered Outcomes Research
    137 schema:publisher Springer Nature
    138 rdf:type schema:Periodical
    139 sg:person.012246573573.48 schema:affiliation grid-institutes:None
    140 schema:familyName Rahim
    141 schema:givenName Tissa
    142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012246573573.48
    143 rdf:type schema:Person
    144 sg:person.016336044014.46 schema:affiliation grid-institutes:None
    145 schema:familyName Bever
    146 schema:givenName Andrea
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016336044014.46
    148 rdf:type schema:Person
    149 sg:person.0750556372.03 schema:affiliation grid-institutes:None
    150 schema:familyName Szabo
    151 schema:givenName Shelagh M.
    152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750556372.03
    153 rdf:type schema:Person
    154 sg:person.07632772614.46 schema:affiliation grid-institutes:None
    155 schema:familyName Manthorne
    156 schema:givenName Jackie
    157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07632772614.46
    158 rdf:type schema:Person
    159 sg:pub.10.1007/bf02596485 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050744497
    160 https://doi.org/10.1007/bf02596485
    161 rdf:type schema:CreativeWork
    162 sg:pub.10.1007/s10198-014-0622-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050041525
    163 https://doi.org/10.1007/s10198-014-0622-4
    164 rdf:type schema:CreativeWork
    165 sg:pub.10.1007/s10508-012-0016-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035291402
    166 https://doi.org/10.1007/s10508-012-0016-6
    167 rdf:type schema:CreativeWork
    168 sg:pub.10.1007/s40271-021-00528-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1138780781
    169 https://doi.org/10.1007/s40271-021-00528-w
    170 rdf:type schema:CreativeWork
    171 sg:pub.10.1038/s41392-019-0099-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123443998
    172 https://doi.org/10.1038/s41392-019-0099-9
    173 rdf:type schema:CreativeWork
    174 grid-institutes:None schema:alternateName Broadstreet HEOR, Vancouver, BC, Canada
    175 Canadian Cancer Survivor Network, Ottawa, ON, Canada
    176 schema:name Broadstreet HEOR, Vancouver, BC, Canada
    177 Canadian Cancer Survivor Network, Ottawa, ON, Canada
    178 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...